MCK
McKesson Corp
$
811.340
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
830.915
Open
820.090
VWAP
812.60
Vol
933.22K
Mkt Cap
100.92B
Low
808.220
Amount
758.33M
EV/EBITDA(TTM)
18.92
Total Shares
129.71M
EV
107.38B
EV/OCF(TTM)
16.40
P/S(TTM)
0.27
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q4
FY2026Q3
FY2026Q2
101.21B
+11.43%
10.646
+5.19%
105.88B
+11.11%
9.762
+21.58%
103.80B
+10.84%
8.784
+24.24%
Estimates Revision
The market is revising Upward the revenue expectations for McKesson Corporation (MCK) for FY2026, with the revenue forecasts being adjusted by 0.66% over the past three months. During the same period, the stock price has changed by 14.12%.
Revenue Estimates for FY2026
Revise Upward
+0.66%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
+2.48%
In Past 3 Month
Stock Price
Go Up
+14.12%
In Past 3 Month
14 Analyst Rating
3.59% Upside
Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is 840.50 USD with a low forecast of 770.00 USD and a high forecast of 900.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
2 Hold
0 Sell
Strong Buy
3.59% Upside
Current: 811.340
Low
770.00
Averages
840.50
High
900.00
3.59% Upside
Current: 811.340
Low
770.00
Averages
840.50
High
900.00
UBS
Kevin Caliendo
Buy
maintain
$860 -> $920
2025-10-27
Reason
UBS
Kevin Caliendo
Price Target
$860 -> $920
2025-10-27
maintain
Buy
Reason
UBS analyst Kevin Caliendo raised the firm's price target on McKesson to $920 from $860 and keeps a Buy rating on the shares.
JPMorgan
NULL -> Overweight
maintain
$821 -> $853
2025-09-26
Reason
JPMorgan
Price Target
$821 -> $853
2025-09-26
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on McKesson to $853 from $821 and keeps an Overweight rating on the shares.
UBS
Buy
maintain
$820 -> $860
2025-09-24
Reason
UBS
Price Target
$820 -> $860
2025-09-24
maintain
Buy
Reason
UBS raised the firm's price target on McKesson to $860 from $820 and keeps a Buy rating on the shares. The company's strong cash flow conversion and ongoing ability to reinvest in new growth markets while divesting slowing or underperforming assets continues to generate improving return on invested capital, the analyst tells investors in a research note. RxTS appears to be the driver of near-term outperformance, which lifts the FY26 outlook, the firm says.
Wells Fargo
Equal Weight
maintain
$772 -> $816
2025-09-24
Reason
Wells Fargo
Price Target
$772 -> $816
2025-09-24
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on McKesson to $816 from $772 and keeps an Equal Weight rating on the shares. The firm notes the company hosted an Investor Day and increased both FY26 EPS guidance and long-term EPS targets. Key growth opportunities in go-forward businesses remain similar thematically with focus on specialty and services, Wells adds.
Morgan Stanley
Erin Wright
Overweight
maintain
$810 -> $857
2025-09-24
Reason
Morgan Stanley
Erin Wright
Price Target
$810 -> $857
2025-09-24
maintain
Overweight
Reason
Morgan Stanley analyst Erin Wright raised the firm's price target on McKesson to $857 from $810 and keeps an Overweight rating on the shares after the company met and surpassed the high bar set into investor day by increasing FY26 EPS guidance by 80c at the midpoint. Updated long-term guidance "also delivered," says the analyst, who contends that McKesson's transparency "should be well appreciated and leaves little to pick at."
Citi
Daniel Grosslight
Buy
maintain
$820 -> $860
2025-09-24
Reason
Citi
Daniel Grosslight
Price Target
$820 -> $860
2025-09-24
maintain
Buy
Reason
Citi analyst Daniel Grosslight raised the firm's price target on McKesson to $860 from $820 and keeps a Buy rating on the shares following the investor day. The firm views the company's better than expected fiscal 2026 guidance raise as a surprise.
See All Ratings
Valuation Metrics
The current forward P/E ratio for McKesson Corp (MCK.N) is 20.35, compared to its 5-year average forward P/E of 14.31. For a more detailed relative valuation and DCF analysis to assess McKesson Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Overvalued
5Y Average PE
14.31
Current PE
20.35
Overvalued PE
17.58
Undervalued PE
11.04
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
10.84
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
13.14
Undervalued EV/EBITDA
8.54
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.15
Current PS
811.34
Overvalued PS
42.26
Undervalued PS
-37.96
Financials
Annual
Quarterly
FY2026Q1
YoY :
+23.39%
97.83B
Total Revenue
FY2026Q1
YoY :
+1.32%
1.08B
Operating Profit
FY2026Q1
YoY :
-13.44%
831.00M
Net Income after Tax
FY2026Q1
YoY :
-10.71%
6.25
EPS - Diluted
FY2026Q1
YoY :
-28.44%
-1.11B
Free Cash Flow
FY2026Q1
YoY :
-13.47%
3.34
Gross Profit Margin - %
FY2026Q1
YoY :
+44.23%
1.50
FCF Margin - %
FY2026Q1
YoY :
-29.75%
0.85
Net Margin - %
FY2026Q1
YoY :
-18.33%
59.96
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
44.1M
USD
5
6-9
Months
17.0M
USD
13
0-12
Months
17.3M
USD
7
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
293.4K
Volume
3
0-12
Months
304.7K
Volume
8
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
59.6K
Volume
Months
0-12
4
136.3K
Volume
Months
Congress Trading
Congress areSelling! The selling amount has increased100%over the last month.
Sold
0-3
Months
16.0K
USD
2
3-6
Months
8.0K
USD
1
6-9
Months
40.5K
USD
2
0-12
Months
16.0K
USD
2
Bought
0-3
2
16.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
9
72.0K
USD
Months
0-12
2
16.0K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
44.1M
USD
5
6-9
Months
17.0M
USD
13
0-12
Months
17.3M
USD
7
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MCK News & Events
Events Timeline
2025-10-22 (ET)
2025-10-22
06:26:41
Trump Administration Readies New Investigation into U.S. Pharmaceutical Pricing, According to FT
2025-10-20 (ET)
2025-10-20
08:39:37
Citius Oncology Signs Distribution Deal with McKesson
2025-09-23 (ET)
2025-09-23
09:55:01
Significant Early Gainers in Liquid Options on September 23rd
Sign Up For More Events
Sign Up For More Events
News
4.5
10-31NASDAQ.COMSignificant ETF Withdrawals: USMV, MCK, APH, MSI
3.0
10-30NASDAQ.COMGuru's In-Depth Analysis Report on MCK
7.5
10-20NASDAQ.COMCitius Oncology Signs Distribution Agreement with McKesson for LYMPHIR
Sign Up For More News
People Also Watch
CL
Colgate-Palmolive Co
77.050
USD
+0.71%
EPD
Enterprise Products Partners LP
30.790
USD
-2.50%
AJG
Arthur J. Gallagher & Co.
249.490
USD
-4.79%
GD
General Dynamics Corp
344.900
USD
+0.07%
EQNR
Equinor ASA
23.960
USD
-0.04%
BMO
Bank of Montreal
124.180
USD
+0.41%
REGN
Regeneron Pharmaceuticals Inc
651.800
USD
-0.34%
DASH
DoorDash Inc
254.370
USD
+0.12%
FTNT
Fortinet Inc
86.430
USD
+2.65%
ZTS
Zoetis Inc
144.090
USD
-0.01%
FAQ
What is McKesson Corp (MCK) stock price today?
The current price of MCK is 811.34 USD — it has decreased -1.72 % in the last trading day.
What is McKesson Corp (MCK)'s business?
What is the price predicton of MCK Stock?
What is McKesson Corp (MCK)'s revenue for the last quarter?
What is McKesson Corp (MCK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for McKesson Corp (MCK)'s fundamentals?
How many employees does McKesson Corp (MCK). have?